Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis

Must Read

List of Guaranty Trust Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...

Here is the list of Providus Bank Branches in Lagos

A little over two years after it was granted a commercial banking license with regional authorization by the Central...

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust; Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved; DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa; Leishmaniasis, which is transmitted by the sandfly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year.

Novartis and the Drugs for Neglected Diseases initiative (DNDi)a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust. Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials. In addition, it will drive pharmaceutical development and regulatory submissions. Upon approval, Novartis has committed to distributing the drug on an affordable basis worldwide with a focus on maximizing access in endemic countries.

DNDwill lead Phase II and Phase III clinical development, with the first Phase II study scheduled to start in early 2021 in India. Additional trials are planned to take place in East Africa, which has the highest burden of visceral leishmaniasis.

- Advertisement -

Existing treatments for visceral leishmaniasis are simply not good enough. They are too long, increasingly ineffective, and can be toxic, painful, and costly,” said Dr Bernard Pécoul, Executive Director of DNDi.Our hope is to radically transform this by developing new oral drugs that are affordable, safe, effective, easy to take, and can also be adapted to meet the treatment needs of patients in different countries.”

Over one billion people worldwide are at risk of leishmaniasis, which is transmitted by the bite of a sandfly. Visceral leishmaniasis, also known as kala-azar, is the most serious form of leishmaniasis, causing fever, weight loss, spleen and liver enlargement, and if left untreated, death. There are an estimated 50 000 to 90 000 new cases per year. Treating the disease is complex as it is dependent on the species of infecting parasite and the country, as treatment responses differ from region to region.

Novartis has a long-term commitment to neglected tropical diseases that spans several decades. Diseases caused by kinetoplastid parasites, such as leishmaniasis, are one of our strategic research priorities and, together with our partners, we have developed a promising portfolio of drug candidates,” said Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis.We are excited to collaborate with DNDi to reimagine treatment options for people with leishmaniasis around the world.”

Broader partnerships
The collaboration between DNDand Novartis is aligned with a broader program with Wellcome and other partners to develop new combinations of entirely new, all-orally acting chemical entities, to treat visceral leishmaniasis and cutaneous leishmaniasis, another form of the disease.

- Advertisement -
Read Also:  Airtel Africa Announces Partnership With Ecobank

The program brings together a strong consortium of R&D partners, including the University of Dundee, GSK, Pfizer, TB Alliance, and Takeda Pharmaceutical Company Limited. These partners have built a portfolio of lead series, pre-clinical and clinical drug candidates, originating from different chemical classes with different mechanisms of action against leishmania parasites. 

We are delighted to be partnering with Novartis from drug development to delivering a promising new oral treatment for visceral leishmaniasis. Together, we can contribute to sustaining elimination efforts in India and altering the treatment landscape in East Africa,” said Dr Fabiana Alves, Head of Visceral Leishmaniasis Clinical Program at DNDi.

- Advertisement -
Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral LeishmaniasisNovartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral LeishmaniasisNovartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis

Latest News

Reckitt Benckiser, MultiChoice, Nigerian Breweries, Coca-Cola make list of organisations giving the world hope amid COVID-19

With the cloud of uncertainty and fear brought upon the world in the first half of the year 2020...

GBfoods completes N20 Billion Tomato Processing Factory in Kebbi

Lagos, Nigeria - GBfoods, a global leader in culinary product manufacturing, in partnership with the Central Bank of Nigeria (CBN), Kebbi State Government and...

COVID-19: ADVAN Supports NANS, BJAN, Petty Traders With Palliatives (Photos)

The Advertisers Association of Nigeria (ADVAN), the umbrella body for advertisers in the country, has extended some measure of palliatives to three distinct groups to cushion...

Four strategies for helping women in fragile settings succeed in the digital economy

The coronavirus (COVID-19) pandemic is disproportionately impacting women’s livelihoods. Young women are more prone to unemployment and under-employment than men, and many work in service and informal sector...

How To Apply For NPower 2020 Recruitment

The NPower program was launched a few years ago and became one of the top opportunities for young individuals to begin their careers in...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral LeishmaniasisNovartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis